Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cadrenal Therapeutics, Inc.

11.49
+0.08000.70%
Post-market: 11.490.00000.00%19:37 EDT
Volume:9.12K
Turnover:104.32K
Market Cap:22.60M
PE:-1.27
High:11.58
Open:11.58
Low:11.25
Close:11.41
Loading ...

Company Profile

Company Name:
Cadrenal Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2022
Employees:
4
Office Location:
822 A1A North,Suite 306,Ponte Vedra,Florida,United States
Zip Code:
32082
Fax:
- -
Introduction:
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Directors

Name
Position
Quang Pham
Chairman of the Board and Chief Executive Officer
Glynn Wilson
Independent Director
John Raymond Murphy
Independent Director
Steven Zelenkofske
Independent Director

Shareholders

Name
Position
Quang Pham
Chairman of the Board and Chief Executive Officer
Jeffrey Cole
Chief Operating Officer
Matthew Szot
Chief Financial Officer and Principal Accounting Officer
James J. Ferguson, III
Chief Medical Officer